Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 8 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(57.1%)

Phase 2

2(28.6%)

Early Phase 1

1(14.3%)

7Total

Phase 1(4)

Phase 2(2)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT00201903Completed

The Roles of Tissue Factor in Malignant Gliomas

Role: collaborator

NCT00213278Phase 2Completed

Phase 2 Study of Vinblastine in Children With Recurrent or Refractory Low Grade Glioma

Role: collaborator

NCT00188175Phase 2Completed

IMRT Lower Limb Soft Tissue Sarcoma

Role: collaborator

NCT00197522Phase 1Completed

Administration of Autologous Dendritic Cells (DCs) Infected With an Adenovirus Expressing Her-2

Role: collaborator

NCT00162929Phase 1Completed

Her-2/Neu in Patients With Metastatic Breast Cancer (AdHERe)

Role: collaborator

NCT00307229Phase 1Completed

Adenovirus Encoding Rat HER-2 in Patients With Metastatic Breast Cancer (AdHER2.1)

Role: collaborator

NCT00188565Phase 1Completed

Celebrex With Preoperative Chemoradiation - Rectal Cancer

Role: collaborator

NCT00221169Early Phase 1Completed

Role of PET CT in Determining Target Volumes in Radiation Therapy for Lung Cancer

Role: collaborator

NCT00228124Unknown

PR.7 Companion Trial: Effect of Intermittent Versus Continuous Androgen Suppression on Bone Loss and Body Composition

Role: lead

All 9 trials loaded